New hope for Tough-to-Treat gynecologic cancers

NCT ID NCT06906341

Recruiting now Disease control Sponsor: Corcept Therapeutics Source: ClinicalTrials.gov ↗

Summary

This study is testing whether adding an experimental drug called relacorilant to standard chemotherapy helps control advanced gynecologic cancers. It will enroll about 270 patients with ovarian, fallopian tube, peritoneal, or endometrial cancer that has returned or spread. The main goal is to see if the combination slows cancer growth and is safe for patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

014
RECRUITING

San Francisco, California, 94143, United States
108
RECRUITING

Leuven, 3000, Belgium
115
RECRUITING

Barcelona, 08035, Spain
121
RECRUITING

Milwaukee, Wisconsin, 53226, United States
122
RECRUITING

Milan, 20141, Italy
124
RECRUITING

Rome, 00168, Italy
127
RECRUITING

Pittsburgh, Pennsylvania, 15213, United States
150
RECRUITING

Palo Alto, California, 94304, United States
255
RECRUITING

Berlin, 10117, Germany
292
RECRUITING

Albuquerque, New Mexico, 97102, United States
293
RECRUITING

Torino, 10128, Italy
295
RECRUITING

Pavia, 27100, Italy
300
RECRUITING

Norfolk, Virginia, 23502, United States
304
RECRUITING

Centerville, Ohio, 45459, United States
306
RECRUITING

Lille, 59000, France
307
RECRUITING

Nancy, 54100, France
308
RECRUITING

Toulouse, 31059, France
310
RECRUITING

Nice, 06100, France
319
RECRUITING

Treviso, 31100, Italy
321
RECRUITING

Catania, 95126, Italy
323
RECRUITING

Plérin, 22190, France
324
RECRUITING

Pierre-Bénite, 69495, France
325
RECRUITING

Hasselt, 3500, Belgium
326
RECRUITING

Charleroi, 6000, Belgium
328
RECRUITING

Aalst, 9300, Belgium
329
RECRUITING

Siedlce, 08-MO, Poland
330
RECRUITING

Valencia, 46026, Spain
334
RECRUITING

Kansas City, Missouri, 64132, United States
341
RECRUITING

Gdynia, 81-519, Poland
349
RECRUITING

Badalona, 08916, Spain
396
RECRUITING

Seoul, Gangnam-gu, 06351, South Korea
397
RECRUITING

Gyeonggi-do, Goyang-si, 10408, South Korea
398
RECRUITING

Seoul, Seodaemun-gu, 03722, South Korea
399
RECRUITING

Seoul, Jongno-gu, 03080, South Korea
403
RECRUITING

Seoul, Songpa-gu, 05505, South Korea
516
RECRUITING

Milan, 20159, Italy
517
RECRUITING

Eugene, Oregon, 97401, United States
518
RECRUITING

Minneapolis, Minnesota, 55404, United States
519
RECRUITING

Aachen, 52074, Germany
520
RECRUITING

Kempten, 87439, Germany
521
RECRUITING

St Louis, Missouri, 63110, United States
522
RECRUITING

Fairfax, Virginia, 22031, United States
523
RECRUITING

Seoul, Seocho-gu, 06591, South Korea
543
RECRUITING

West Palm Beach, Florida, 33041, United States
544
RECRUITING

Fort Myers, Florida, 33901, United States

Conditions

Explore the condition pages connected to this study.

ENDOMETRIAL CANCER FALLOPIAN TUBE CANCER OVARIAN CANCER PERITONEAL NEOPLASMS